These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82. Treatment of Neurogenetic Developmental Conditions: From 2016 into the Future. van Karnebeek CD; Bowden K; Berry-Kravis E Pediatr Neurol; 2016 Dec; 65():1-13. PubMed ID: 27697313 [TBL] [Abstract][Full Text] [Related]
84. The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders. Braat S; Kooy RF Neuron; 2015 Jun; 86(5):1119-30. PubMed ID: 26050032 [TBL] [Abstract][Full Text] [Related]
85. Positron emission tomography methods with potential for increased understanding of mental retardation and developmental disabilities. Sundaram SK; Chugani HT; Chugani DC Ment Retard Dev Disabil Res Rev; 2005; 11(4):325-30. PubMed ID: 16240413 [TBL] [Abstract][Full Text] [Related]
86. Cognitive-adaptive disabilities. Calles JL Pediatr Clin North Am; 2011 Feb; 58(1):189-203, xii. PubMed ID: 21281856 [TBL] [Abstract][Full Text] [Related]
87. Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment. Curatolo P; Napolioni V; Moavero R J Child Neurol; 2010 Jul; 25(7):873-80. PubMed ID: 20207609 [TBL] [Abstract][Full Text] [Related]
88. Pathways to drug development for autism spectrum disorders. Hampson DR; Gholizadeh S; Pacey LK Clin Pharmacol Ther; 2012 Feb; 91(2):189-200. PubMed ID: 22205199 [TBL] [Abstract][Full Text] [Related]
89. Identifying patterns of developmental delays can help diagnose neurodevelopmental disorders. Tervo RC Clin Pediatr (Phila); 2006 Jul; 45(6):509-17. PubMed ID: 16893855 [No Abstract] [Full Text] [Related]
90. New innovations: therapeutic opportunities for intellectual disabilities. Picker JD; Walsh CA Ann Neurol; 2013 Sep; 74(3):382-90. PubMed ID: 24038210 [TBL] [Abstract][Full Text] [Related]
91. People with intellectual disability: what do we know about adulthood and life expectancy? Coppus AM Dev Disabil Res Rev; 2013; 18(1):6-16. PubMed ID: 23949824 [TBL] [Abstract][Full Text] [Related]
92. Autism spectrum disorders and epigenetics. Grafodatskaya D; Chung B; Szatmari P; Weksberg R J Am Acad Child Adolesc Psychiatry; 2010 Aug; 49(8):794-809. PubMed ID: 20643313 [TBL] [Abstract][Full Text] [Related]
93. Health supervision for children with fragile X syndrome. Hersh JH; Saul RA; Pediatrics; 2011 May; 127(5):994-1006. PubMed ID: 21518720 [TBL] [Abstract][Full Text] [Related]
94. Emerging pharmacotherapies for neurodevelopmental disorders. Wetmore DZ; Garner CC J Dev Behav Pediatr; 2010 Sep; 31(7):564-81. PubMed ID: 20814256 [TBL] [Abstract][Full Text] [Related]
95. Role of ESSENCE for preschool children with neurodevelopmental disorders. Neville B Brain Dev; 2013 Feb; 35(2):128-32. PubMed ID: 22874529 [TBL] [Abstract][Full Text] [Related]
96. The pathophysiology, medical management and dental implications of fragile X, Rett, and Prader-Willi syndromes. Friedlander AH; Yagiela JA; Paterno VI; Mahler ME J Calif Dent Assoc; 2003 Sep; 31(9):693-702. PubMed ID: 14560873 [TBL] [Abstract][Full Text] [Related]
97. Prader-Willi syndrome. Wattendorf DJ; Muenke M Am Fam Physician; 2005 Sep; 72(5):827-30. PubMed ID: 16156341 [TBL] [Abstract][Full Text] [Related]
98. Approach to the genetic evaluation of the child with autism. Toriello HV Pediatr Clin North Am; 2012 Feb; 59(1):113-28, xi. PubMed ID: 22284797 [TBL] [Abstract][Full Text] [Related]